very hot tip, page-4

Info on progress and Negotiations with Interested parties. SP dropped due to delays caused with some defective product by supplier, all sorted now and also new formulation will reduce costs 50%. 4 Billion $ industry re ulcers. (potential to become default dressing technology)

TIS - ABN Amro rates the stock as Buy(this was before product defect which has been sorted)
BROKER NEWS - 08/02/2008


While revising down its price target to reflect market volatility the broker retains its positive rating, noting a clinical trial for the company's CitroGro compound is set to commence this month. Sector: Pharmaceuticals & Biotechnology.
Target price is $0.57. Current Price is $0.23. Difference: $0.34 - (brackets indicate current price is over target). If TIS meets the ABN Amro target it will return approximately 60% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Should see decent SP rise but depends how long you want to wait as a short term swing trader. Announcement/s the key to this swing. Good luck.